Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730793 · ClinicalTrials.gov registry record · Phase 2
Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease
A Phase 2 study, sponsored by Virginia Commonwealth University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02730793 is a Phase 2 study that was terminated before completion, run by Virginia Commonwealth University. The registered enrollment target is 5 participants.
The verdict
NCT02730793, a Phase 2 study, was terminated before completion, sponsored by Virginia Commonwealth University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical Center (VCU) and Eastern Virginia Medical School (EVMS). Potential subjects will be identified in each site's CF clinic.
Interventions
- DRUG Nasal Placebo
- DRUG Oral Aztreonam
- DRUG Nasal Aztreonam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01 |
| Est. Completion | 2019-09-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730793
The ClinicalTrials.gov registry entry for NCT02730793 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Virginia Commonwealth University, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Nasal Placebo is the first listed.
NCT02730793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730793 about?
NCT02730793 is a clinical study titled "Aztreonam Aerosol to Treat Cystic Fibrosis Nasal Disease". This study is designed as a masked, two center, randomized, placebo-controlled pilot study to evaluate the safety and efficacy of nasal and oral inhalation of 75 mg aztreonam in subjects with CF and lung infection due to PA. The study will involve two sites: Virginia Commonwealth University Medical ...
What is the current status of trial NCT02730793?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-01. Estimated completion is 2019-09-19.
What interventions are being tested in trial NCT02730793?
The interventions under investigation include: Nasal Placebo (DRUG), Oral Aztreonam (DRUG), Nasal Aztreonam (DRUG).
Who is sponsoring clinical trial NCT02730793?
This trial is sponsored by Virginia Commonwealth University, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.